SW · LONN.SW
Lonza Group AG
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Basel 4002
- Website
- lonza.com
Price · as of 2025-12-31
$479.20
Market cap 37.19B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $311.26 | -35.05% |
| Intrinsic Value(DCF) | $218.18 | -54.47% |
| Graham-Dodd Method(GD) | $109.99 | -77.05% |
| Graham Formula(GF) | $102.18 | -78.68% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $35.43 | $30.87 | $0.00 | $5.92 | $23.52 |
| 2012 | $49.89 | $35.68 | $434.50 | $9.00 | $169.12 |
| 2013 | $74.77 | $52.98 | $38.77 | $0.00 | $0.00 |
| 2014 | $107.48 | $68.71 | $0.91 | $9.68 | $43.87 |
| 2015 | $137.34 | $89.58 | $6.64 | $8.30 | $64.90 |
| 2016 | $161.62 | $116.12 | $8.43 | $11.50 | $93.13 |
| 2017 | $225.08 | $148.58 | $23.95 | $49.52 | $189.27 |
| 2018 | $286.31 | $184.89 | $91.76 | $29.23 | $217.74 |
| 2019 | $320.65 | $180.63 | $4.07 | $40.59 | $0.00 |
| 2020 | $524.30 | $276.89 | $3.06 | $67.58 | $175.40 |
| 2021 | $647.45 | $340.99 | $30.08 | $243.87 | $1,080.80 |
| 2022 | $522.68 | $299.09 | $46.92 | $140.97 | $367.93 |
| 2023 | $467.13 | $263.92 | $13.48 | $82.42 | $140.15 |
| 2024 | $544.59 | $314.90 | $25.55 | $67.65 | $53.81 |
| 2025 | $530.20 | $311.26 | $0.00 | $109.99 | $102.18 |
AI valuation
Our deep-learning model estimates Lonza Group AG's (LONN.SW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $311.26
- Current price
- $479.20
- AI upside
- -35.05%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$218.18
-54.47% upside
Graham-Dodd
$109.99
-77.05% upside
Graham Formula
$102.18
-78.68% upside
About Lonza Group AG
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.
- CEO
- Wolfgang Wienand
- Employees
- 18K
- Beta
- 0.93
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($218.18 ÷ $479.20) − 1 = -54.47% (DCF, example).